What the company does
Yungjin Pharm is a South Korean pharmaceutical company that develops and supplies medicines for human health.
Its products reach patients and healthcare providers through the domestic pharmaceutical market. The company is listed on KOSPI, Korea's main stock exchange. The filing does not provide sufficient detail to identify a single dominant structural fact about its business model or product mix.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue · FY2025
US$184.2M
▲ +0.9% YoY
Operating profit · FY2025
US$2.5M
▼ −60.8% YoY
Net income · FY2025
−US$165K
Turned to loss
Revenue
- FY2023US$170.2M
- FY2024US$182.6M
- FY2025US$184.2M
Operating profit
- FY2023US$2.3M
- FY2024US$6.3M
- FY2025US$2.5M
Net income
- FY2023−US$2.8M
- FY2024US$893.3K
- FY2025−US$165K
Key ratios (FY2025)
ROE
-0.3%
Debt/Eq
186.9%
Op. margin
1.3%
Net margin
-0.1%
Rev. YoY
▲ +0.9%
Filings
All disclosures · English when translatedPrice charts coming soon
Interactive price history isn't here yet. Would you use it?